Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2011

01-01-2011 | Brief Report

A recombination-based method to characterize human BRCA1 missense variants

Authors: Lucia Guidugli, Chiara Rugani, Grazia Lombardi, Paolo Aretini, Alvaro Galli, Maria Adelaide Caligo

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Abstract

Many missense variants in BRCA1 are of unclear clinical significance. Functional and genetic approaches have been proposed for elucidating the clinical significance of such variants. The purpose of this study was to evaluate BRCA1 missense variants for their effect on both homologous recombination (HR) and non homologous end joining (NHEJ). HR frequency evaluation: HeLaG1 cells, containing a stably integrated plasmid that allows us to measure HR events by gene conversion events, were transfected with the pcDNA3β expression vector containing the BRCA1-wild-type (BRCA1 wild type) or the BRCA1-unclassified variants (BRCA1-UCVs). The NHEJ was measured by a random plasmid integration assay. The assays suggested a BRCA1 involvement mainly in the NHEJ. As a matter of fact, the Y179C and the A1789T variant significantly altered the NHEJ activity as compared to the wild type, suggesting that they may be related to BRCA1-associated pathogenicity by affecting this function. The variants N550H and I1766S, and the mutation M1775R did not alter the NHEJ frequency. These data, besides proposing a method for the study of BRCA1 variants' effect on HR and NHEJ, highlighted the need for a range of functional assays to be performed to identify variants with altered function.
Literature
1.
go back to reference Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R (1998) Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2(3):317–328. doi:S1097-2765(00)80276-2 CrossRefPubMed Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R (1998) Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2(3):317–328. doi:S1097-2765(00)80276-2 CrossRefPubMed
5.
go back to reference Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV (2004) Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41(7):492–507CrossRefPubMed Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV (2004) Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41(7):492–507CrossRefPubMed
7.
go back to reference Couch FJ, Rasmussen LJ, Hofstra R, Monteiro AN, Greenblatt MS, de Wind N, IARC Unclassified Genetic Variants Working Group (2008) Assessment of functional effects of unclassified genetic variants. Hum Mutat 29(11):1314–1326CrossRefPubMed Couch FJ, Rasmussen LJ, Hofstra R, Monteiro AN, Greenblatt MS, de Wind N, IARC Unclassified Genetic Variants Working Group (2008) Assessment of functional effects of unclassified genetic variants. Hum Mutat 29(11):1314–1326CrossRefPubMed
9.
go back to reference Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW (1996) The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 85(7):1009–1023. doi:S0092-8674(00)81302-1 CrossRefPubMed Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW (1996) The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 85(7):1009–1023. doi:S0092-8674(00)81302-1 CrossRefPubMed
10.
go back to reference Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH (1999) Association of BRCA1 with the hrad50-hmre11–p95 complex and the DNA damage response. Science 285(5428):747–750CrossRefPubMed Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH (1999) Association of BRCA1 with the hrad50-hmre11–p95 complex and the DNA damage response. Science 285(5428):747–750CrossRefPubMed
11.
go back to reference Bau DT, Fu YP, Chen ST, Cheng TC, Yu JC, Wu PE, Shen CY (2004) Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res 64(14):5013–5019CrossRefPubMed Bau DT, Fu YP, Chen ST, Cheng TC, Yu JC, Wu PE, Shen CY (2004) Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res 64(14):5013–5019CrossRefPubMed
13.
go back to reference Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, Koller BH (1999) BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a BRCA1 transgene. Oncogene 18(55):7900–7907. doi:10.1038/sj.onc.1203334 CrossRefPubMed Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, Koller BH (1999) BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a BRCA1 transgene. Oncogene 18(55):7900–7907. doi:10.​1038/​sj.​onc.​1203334 CrossRefPubMed
14.
go back to reference Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31(13):3812–3814CrossRefPubMed Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31(13):3812–3814CrossRefPubMed
15.
go back to reference Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous snps: server and survey. Nucleic Acids Res 30(17):3894–3900CrossRefPubMed Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous snps: server and survey. Nucleic Acids Res 30(17):3894–3900CrossRefPubMed
21.
go back to reference Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz JL, Nathanson KL, Sali A, Goldgar D, Couch FJ, Radice P, Monteiro AN (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67(4):1494–1501. doi:67/4/1494[pii]10.1158/0008-5472.CAN-06-3297 CrossRefPubMed Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz JL, Nathanson KL, Sali A, Goldgar D, Couch FJ, Radice P, Monteiro AN (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67(4):1494–1501. doi:67/​4/​1494[pii]10.​1158/​0008-5472.​CAN-06-3297 CrossRefPubMed
22.
go back to reference Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, Scholl T (2005) Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 65(21):10096–10103. doi:65/21/10096[pii]10.1158/0008-5472.CAN-05-1241 CrossRefPubMed Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, Scholl T (2005) Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 65(21):10096–10103. doi:65/​21/​10096[pii]10.​1158/​0008-5472.​CAN-05-1241 CrossRefPubMed
23.
go back to reference Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS (2008) Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 29(11):1265–1272. doi:10.1002/humu.20897 CrossRefPubMed Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS (2008) Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 29(11):1265–1272. doi:10.​1002/​humu.​20897 CrossRefPubMed
24.
go back to reference Tavtigian SV, Greenblatt MS, Goldgar DE, Boffetta P (2008) Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Hum Mutat 29(11):1261–1264. doi:10.1002/humu.20903 CrossRefPubMed Tavtigian SV, Greenblatt MS, Goldgar DE, Boffetta P (2008) Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Hum Mutat 29(11):1261–1264. doi:10.​1002/​humu.​20903 CrossRefPubMed
25.
go back to reference Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A, Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K, Brown M, Easton D, Tavtigian SV, Goldgar D, Spurdle AB (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66(4):2019–2027. doi:66/4/2019[pii]10.1158/0008-5472.CAN-05-3546 CrossRefPubMed Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A, Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K, Brown M, Easton D, Tavtigian SV, Goldgar D, Spurdle AB (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66(4):2019–2027. doi:66/​4/​2019[pii]10.​1158/​0008-5472.​CAN-05-3546 CrossRefPubMed
27.
go back to reference Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, Chenevix-Trench G, ConFab K, Caldes T, de la Hoya M, Lindquist S, Tavtigian SV, Goldgar D, Borg A, Narod SA, Monteiro AN (2005) Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 42(2):138–146. doi:42/2/138[pii]10.1136/jmg.2004.024711 CrossRefPubMed Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, Chenevix-Trench G, ConFab K, Caldes T, de la Hoya M, Lindquist S, Tavtigian SV, Goldgar D, Borg A, Narod SA, Monteiro AN (2005) Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 42(2):138–146. doi:42/​2/​138[pii]10.​1136/​jmg.​2004.​024711 CrossRefPubMed
28.
go back to reference Galli A, Schiestl RH (1996) Effects of salmonella assay negative and positive carcinogens on intrachromosomal recombination in G1-arrested yeast cells. Mutat Res 370(3–4):209–221PubMed Galli A, Schiestl RH (1996) Effects of salmonella assay negative and positive carcinogens on intrachromosomal recombination in G1-arrested yeast cells. Mutat Res 370(3–4):209–221PubMed
29.
go back to reference Galli A, Schiestl RH (1995) Salmonella test positive and negative carcinogens show different effects on intrachromosomal recombination in G2 cell cycle arrested yeast cells. Carcinogenesis 16(3):659–663CrossRefPubMed Galli A, Schiestl RH (1995) Salmonella test positive and negative carcinogens show different effects on intrachromosomal recombination in G2 cell cycle arrested yeast cells. Carcinogenesis 16(3):659–663CrossRefPubMed
30.
go back to reference Caligo MA, Bonatti F, Guidugli L, Aretini P, Galli A (2009) A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance. Hum Mutat 30(1):123–133. doi:10.1002/humu.20817 CrossRefPubMed Caligo MA, Bonatti F, Guidugli L, Aretini P, Galli A (2009) A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance. Hum Mutat 30(1):123–133. doi:10.​1002/​humu.​20817 CrossRefPubMed
31.
go back to reference Mao Z, Bozzella M, Seluanov A, Gorbunova V (2008) Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair 7(10):1765–1771CrossRefPubMed Mao Z, Bozzella M, Seluanov A, Gorbunova V (2008) Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair 7(10):1765–1771CrossRefPubMed
32.
go back to reference Zhong Q, Boyer TG, Chen PL, Lee WH (2002) Deficient nonhomologous end-joining activity in cell-free extracts from BRCA1-null fibroblasts. Cancer Res 62(14):3966–3970PubMed Zhong Q, Boyer TG, Chen PL, Lee WH (2002) Deficient nonhomologous end-joining activity in cell-free extracts from BRCA1-null fibroblasts. Cancer Res 62(14):3966–3970PubMed
33.
go back to reference Baldeyron C, Jacquemin E, Smith J, Jacquemont C, De Oliveira I, Gad S, Feunteun J, Stoppa-Lyonnet D, Papadopoulo D (2002) A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining. Oncogene 21(9):1401–1410. doi:10.1038/sj.onc.1205200 CrossRefPubMed Baldeyron C, Jacquemin E, Smith J, Jacquemont C, De Oliveira I, Gad S, Feunteun J, Stoppa-Lyonnet D, Papadopoulo D (2002) A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining. Oncogene 21(9):1401–1410. doi:10.​1038/​sj.​onc.​1205200 CrossRefPubMed
Metadata
Title
A recombination-based method to characterize human BRCA1 missense variants
Authors
Lucia Guidugli
Chiara Rugani
Grazia Lombardi
Paolo Aretini
Alvaro Galli
Maria Adelaide Caligo
Publication date
01-01-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1112-8

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine